Target intelligence / Profile preview

Engineered aminoacyl-tRNA synthetase and ribosomal translational machinery

Molecular classification
Enzyme (for aminoacyl-tRNA synthetase), Ribosomal complex (for ribosomal machinery), Other (Synthetic biology tool, not a native biological entity)
01

Overview

Engineered aminoacyl-tRNA synthetase/ribosomal machinery systems are synthetic biology tools comprising: (1) modified aminoacyl-tRNA synthetases, which specifically attach noncanonical amino acids to engineered tRNAs; (2) modified tRNAs that recognize unique or repurposed codons (such as stop codons or quadruplet codons); and (3) in some cases, engineered ribosomes altered to selectively translate these codons within the cell. Together, these allow incorporation of novel amino acids into proteins, enabling an expanded genetic code and the study or production of proteins with new properties. These systems are primarily used in research, biotechnology, and synthetic biology rather than direct therapeutic interventions.

Other names
Orthogonal tRNA synthetase-ribosome systemExpanded genetic code systemEngineered translation machineryOrthogonal translation system
02

Mechanism of action

For engineered aminoacyl-tRNA synthetase: Catalyzes attachment of noncanonical amino acids to engineered tRNAs, enabling their incorporation at designated codons during protein synthesis. For engineered ribosome: Facilitates translation of mRNAs containing unnatural codons, such as quadruplet codons or recoded amber (UAG) stop codons.

03

Biological functions

Protein synthesisGenetic code expansionSite-specific incorporation of noncanonical amino acidsTranslation of synthetic mRNAs
04

Disease associations

Other (primarily research and biotechnology applications; not directly implicated in human disease unless misapplication leads to toxicity)
05

Safety considerations

Off-target incorporation of unnatural amino acids leading to proteotoxicityImpact on global protein synthesis fidelityPossible immunogenicity if used in vivoBiosafety considerations for escape of synthetic organisms
06

Interacting drugs

None in approved clinical use; some antibiotics (e.g., puromycin, chloramphenicol, tetracycline, etc.) target native ribosomal machinery, but not "engineered" systems specifically. For engineered systems, small molecules may be used experimentally to regulate translation.
07

Biomarkers

None established clinically; in experimental systems, may use fluorescent or affinity tags encoded by the noncanonical amino acid.

Beyond the preview

Go deeper on Engineered aminoacyl-tRNA synthetase and ribosomal translational machinery.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Engineered aminoacyl-tRNA synthetase and ribosomal translational machinery.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call